Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Oncology Institute (DFPH) EBT Margin (2021 - 2025)

Historic EBT Margin for Oncology Institute (DFPH) over the last 5 years, with Q3 2025 value amounting to 12.09%.

  • Oncology Institute's EBT Margin rose 40400.0% to 12.09% in Q3 2025 from the same period last year, while for Sep 2025 it was 14.4%, marking a year-over-year increase of 42100.0%. This contributed to the annual value of 16.44% for FY2024, which is 91900.0% up from last year.
  • As of Q3 2025, Oncology Institute's EBT Margin stood at 12.09%, which was up 40400.0% from 14.31% recorded in Q2 2025.
  • Oncology Institute's 5-year EBT Margin high stood at 35.29% for Q1 2022, and its period low was 39.31% during Q1 2023.
  • Moreover, its 5-year median value for EBT Margin was 15.7% (2024), whereas its average is 12.13%.
  • Its EBT Margin has fluctuated over the past 5 years, first skyrocketed by 368900bps in 2022, then plummeted by -746000bps in 2023.
  • Over the past 5 years, Oncology Institute's EBT Margin (Quarter) stood at 24.14% in 2021, then soared by 34bps to 15.92% in 2022, then crashed by -40bps to 22.23% in 2023, then skyrocketed by 41bps to 13.15% in 2024, then increased by 8bps to 12.09% in 2025.
  • Its EBT Margin stands at 12.09% for Q3 2025, versus 14.31% for Q2 2025 and 18.76% for Q1 2025.